Johnson-and-Johnson is a drug manufacturers-general business based in the US. Johnson-and-Johnson stocks (JNJ.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $165.22 – a decrease of 1.33% over the previous week. Johnson-and-Johnson employs 136,000 staff and has a trailing 12-month revenue of around $89.2 billion.
How to buy Johnson-and-Johnson stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: JNJ in this case.
- Research Johnson-and-Johnson stocks. The platform should provide the latest information available.
- Buy your Johnson-and-Johnson stocks. It's that simple.
Is it a good time to buy Johnson-and-Johnson stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Johnson-and-Johnson?
- Has coronavirus impacted Johnson-and-Johnson shares?
- Johnson-and-Johnson shares summary
- Compare share dealing platforms
- Is Johnson-and-Johnson stock a buy or sell?
- Johnson-and-Johnson performance over time
- Can I short Johnson-and-Johnson shares?
- Is Johnson-and-Johnson suitable for ethical investing?
- Are Johnson-and-Johnson shares over-valued?
- Johnson-and-Johnson's financials
- How volatile are Johnson-and-Johnson shares?
- Does Johnson-and-Johnson pay a dividend?
- Have Johnson-and-Johnson shares ever split?
- Other common questions
How has Coronavirus impacted Johnson-and-Johnson's stock price?
Since the stock market crash in March caused by coronavirus, Johnson-and-Johnson's stock price has had significant positive movement.
Its last market close was $164.75, which is 9.00% up on its pre-crash value of $149.93 and 50.93% up on the lowest point reached during the March crash when the stocks fell as low as $109.16.
If you had bought $1,000 worth of Johnson-and-Johnson stocks at the start of February 2020, those stocks would have been worth $740.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,097.24.
Johnson-and-Johnson stock priceUse our graph to track the performance of JNJ stocks over time.
Johnson-and-Johnson stocks at a glance
|Latest market close||$164.75|
|52-week range||$130.313 - $178.93|
|50-day moving average||$173.1686|
|200-day moving average||$167.1124|
|Wall St. target price||$188.88|
|Dividend yield||$4.09 (2.48%)|
|Earnings per share (TTM)||$6.652|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Johnson-and-Johnson price performance over time
|1 week (2021-09-09)||-1.98%|
|1 month (2021-08-19)||-7.74%|
|3 months (2021-06-18)||1.71%|
|6 months (2021-03-19)||2.94%|
|1 year (2020-09-18)||10.44%|
|2 years (2019-09-18)||26.33%|
|3 years (2018-09-18)||17.23%|
|5 years (2016-09-16)||39.32%|
Is Johnson-and-Johnson under- or over-valued?
Valuing Johnson-and-Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson-and-Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson-and-Johnson's P/E ratio
Johnson-and-Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Johnson-and-Johnson stocks trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.
Johnson-and-Johnson's PEG ratio
Johnson-and-Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6794. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson-and-Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Johnson-and-Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$30.7 billion.
The EBITDA is a measure of a Johnson-and-Johnson's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$89.2 billion|
|Operating margin TTM||25.98%|
|Gross profit TTM||USD$54.3 billion|
|Return on assets TTM||8.65%|
|Return on equity TTM||26.81%|
|Market capitalisation||USD$432 billion|
TTM: trailing 12 months
How to short and sell Johnson-and-Johnson stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "JNJ.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 16.4 million Johnson-and-Johnson stocks held short by investors – that's known as Johnson-and-Johnson's "short interest". This figure is 4.8% down from 17.2 million last month.
There are a few different ways that this level of interest in shorting Johnson-and-Johnson stocks can be evaluated.
Johnson-and-Johnson's "short interest ratio" (SIR)
Johnson-and-Johnson's "short interest ratio" (SIR) is the quantity of Johnson-and-Johnson stocks currently shorted divided by the average quantity of Johnson-and-Johnson stocks traded daily (recently around 5.2 million). Johnson-and-Johnson's SIR currently stands at 3.14. In other words for every 100,000 Johnson-and-Johnson stocks traded daily on the market, roughly 3140 stocks are currently held short.
However Johnson-and-Johnson's short interest can also be evaluated against the total number of Johnson-and-Johnson stocks, or, against the total number of tradable Johnson-and-Johnson stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson-and-Johnson's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Johnson-and-Johnson stocks in existence, roughly 10 stocks are currently held short) or 0.0062% of the tradable stocks (for every 100,000 tradable Johnson-and-Johnson stocks, roughly 6 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Johnson-and-Johnson.
Find out more about how you can short Johnson-and-Johnson stock.
Johnson-and-Johnson's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson-and-Johnson.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Johnson-and-Johnson's total ESG risk score
Total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson-and-Johnson's overall score of 35.8 (as at 01/01/2019) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson-and-Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Johnson-and-Johnson's environmental score
Environmental score: 3.79/100
Johnson-and-Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Johnson-and-Johnson's social score
Social score: 25.14/100
Johnson-and-Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Johnson-and-Johnson's governance score
Governance score: 14.87/100
Johnson-and-Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson-and-Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Johnson-and-Johnson's controversy score
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson-and-Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson-and-Johnson has a damaged public profile.
Environmental, social, and governance (ESG) summary
|Total ESG score||35.8|
|Total ESG percentile||72.38|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||4|
Johnson-and-Johnson stock dividends
Dividend payout ratio: 45.35% of net profits
Recently Johnson-and-Johnson has paid out, on average, around 45.35% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.57% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson-and-Johnson shareholders could enjoy a 2.57% return on their shares, in the form of dividend payments. In Johnson-and-Johnson's case, that would currently equate to about $4.09 per share.
While Johnson-and-Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson-and-Johnson may be investing much of the rest of its net profits in future growth.
Johnson-and-Johnson's most recent dividend payout was on 7 September 2021. The latest dividend was paid out to all shareholders who bought their stocks by 23 August 2021 (the "ex-dividend date").
Have Johnson-and-Johnson stocks ever split?
Johnson-and-Johnson stocks were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson-and-Johnson stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Johnson-and-Johnson stocks which in turn could have impacted Johnson-and-Johnson's stock price.
Johnson-and-Johnson stock price volatility
Over the last 12 months, Johnson-and-Johnson's stocks have ranged in value from as little as $130.313 up to $178.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson-and-Johnson's is 0.7047. This would suggest that Johnson-and-Johnson's stocks are less volatile than average (for this exchange).
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Stocks similar to Johnson-and-Johnson
Johnson-and-Johnson in the news
Best Biotech Stocks To Buy Now? 4 For Your Watchlist
Johnson & Johnson gears up for showdown over reorg votes with ex-talc supplier
FDA advisory panel authorizes booster dose for those 65 & older
Frequently asked questions
More on investing
Everything we know about the Civeo Corporation IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
More guides on Finder
How to buy Planet Labs (PL) stock in Canada when it goes public
Everything we know about the Planet Labs IPO, plus information on how to buy in.
How to buy Impossible Foods stock in Canada when it goes public
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
How to buy Samsara stock in Canada when it goes public
Everything we know about the Samsara IPO, plus information on how to buy in.
How to buy Allbirds (BIRD) stock in Canada when it goes public
Everything we know about the Allbirds IPO, plus information on how to buy in.
How to buy Smooth Love Potion (SLP) in Canada
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
How to buy OnlyFans stock in Canada when it goes public
Everything we know about the OnlyFans IPO, plus information on how to buy in.
How to buy Vinco Ventures stock in Canada | $7.77
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
How to buy Weber stock in Canada | $14.99
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
How to buy Chobani stock in Canada when it goes public
Everything we know about the Chobani IPO, plus information on how to buy in.
How to buy Quickswap (QUICK) in Canada
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.